Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
Cancer Medicine ( IF 2.9 ) Pub Date : 2023-01-09 , DOI: 10.1002/cam4.5532
Jianming Xu ₁ , Jiuwei Cui ₂ , Haiping Jiang ₃ , Yan Zeng ₄ , Xiuyu Cong ₄

Affiliation

Inhibition of fibroblast growth factor (FGF) 19-FGF Receptor 4 (FGFR4) signaling demonstrates potent anticancer activity. EVER4010001 is a highly selective FGFR4 inhibitor and pembrolizumab is approved for the treatment of several solid tumors. This study determined the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), pharmacokinetics, safety, and preliminary efficacy of EVER4010001 plus pembrolizumab in patients with advanced solid tumors.

中文翻译：

FGFR4 抑制剂联合派姆单抗治疗晚期实体瘤患者的 1 期剂量递增研究

抑制成纤维细胞生长因子 (FGF) 19-FGF 受体 4 (FGFR4) 信号转导显示出强大的抗癌活性。EVER4010001 是一种高选择性 FGFR4 抑制剂，pembrolizumab 被批准用于治疗多种实体瘤。本研究确定了 EVER4010001 加帕博利珠单抗在晚期实体瘤患者中的最大耐受剂量 (MTD)、推荐的 2 期剂量 (RP2D)、药代动力学、安全性和初步疗效。

更新日期：2023-01-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南